The main objectives of this trial are to investigate safety, tolerability, pharmacokinetics and pharmacodynamics following single rising doses of BI 765250.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
139
SGS Life Science Services - Clinical Research
Edegem, Belgium
Percentage of subjects with treatment-emergent adverse events assessed as drug-related by the investigator
Time frame: Up to 172 days
Area under the concentration-time curve of the analyte in serum over the time interval from 0 extrapolated to infinity (AUC0-∞)
Time frame: Up to 169 days
Maximum measured concentration of the analyte in serum (Cmax)
Time frame: Up to 169 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.